Skip to content
OpenCapital
Get started

Pfizer PFE International Emerging Markets — Revenues:

Other geography segments

International Developed Markets
$3.43B+7.8%

Other financials

Income statement

See full
Revenue$14.5B+5.4%
Gross profit$10.9B+0.3%
Net income$2.7B-9.4%
EPS (diluted)$0.47-9.6%

Balance sheet

See full
Cash & equivalents$1.8B+18.8%
Total debt$64.4B+5.0%
Total equity$90.1B-0.3%
Total assets$207.62B-0.2%

Cash flow

See full
Operating cash flow$2.6B+12.0%
CapEx$436.0M-22.7%
Free cash flow$2.2B+23.0%

Valuation

See full
Market cap$143.68B+11.1%
Enterprise value$206.35B+9.2%
P/E11.9×—
P/S2.3×+0.2×

Profitability

See full
Gross margin73.5%+1.2pp
Net margin15.7%—

Returns & leverage

See full
Return on equity10.6%—
Debt / equity0.7×0.0×
Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's international emerging markets — revenues:.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pfizer's international emerging markets — revenues:?
Pfizer (PFE) reported international emerging markets — revenues: of $2.29B in Q1 2026.
How has Pfizer's international emerging markets — revenues: changed year-over-year?
Pfizer's international emerging markets — revenues: increased by 6.0% year-over-year, from $2.16B to $2.29B.
What is the long-term trend for Pfizer's international emerging markets — revenues:?
Over 3 years (2022 to 2025), Pfizer's international emerging markets — revenues: has grown at a -18.7% compound annual growth rate (CAGR), from $17.32B to $9.31B.
What does international emerging markets — revenues: mean?
Total revenue earned from pharmaceutical sales in developing international markets.
How do you interpret international emerging markets — revenues:?
An increase suggests successful market penetration and rising demand for the company's products in developing economies, while a decrease may indicate regulatory hurdles, currency volatility, or increased local competition.
How does international emerging markets — revenues: compare across companies?
Peers in the pharmaceutical industry typically report this as part of their 'Rest of World' or 'Emerging Markets' geographic segment, often benchmarked against regional GDP growth and local healthcare spending trends.